Kirkland & Ellis

Corporate

Partner

Dr. Mengyu Lu heads the Firm’s Asia capital markets practice. Dr. Lu has extensive experience in initial public offerings, SPACs, pre-IPO financings, mergers and acquisitions, and various follow-on offerings or compliance matters by listed companies. She is particularly well recognized in advising issuers in the “new economy” sectors, including healthcare, semiconductor, artificial intelligence, TMT and consumer sectors. In addition to corporate issuers, she also advises major investment banks, private equity and venture capital firms on capital markets and M&A matters. Her major corporate clients include, among others, Super Hi, ZG Group, NIO, Will Semiconductor and Kelun Biotech.

Dr. Lu was recognized as a leading lawyer for China equity capital markets by Chambers Global and Chambers Greater China, a “Leading Individual” for Hong Kong equity capital markets by Legal 500, and a “Highly Regarded” lawyer for Hong Kong capital markets by IFLR1000. IFLR named her to its list of 2021 “Asia Best Lawyers”, and Asian Legal Business named her to its 2021 Asia “40 under 40” list. She was also listed in China Business Law Journal’s “China’s Elite 100 Lawyers” in 2016-2018 and 2020-2021.

English, Mandarin, Cantonese

Chinese Academy of Social Sciences, Ph.D., Economics

Duke University School of Law, LL.M.

China University of Political Science and Law, LL.B.